Recovery Guide

Chapter 2 of 7

What Is 7-OH? Why It Hits So Much Harder Than Kratom Leaf

Concentrated 7-OH products can deliver powerful opioid effects despite being sold under the kratom name. This article examines how they differ from leaf products, what emerging safety reports show, and where treatment and federal regulation stand.
Updated October 19, 2026 · 8 min read
Reviewed by Chris Burwash

Share On Social

Facebook
Twitter
LinkedIn
Pinterest
Reddit
Table of Contents
Man in a pickup outside an Arizona gas station looking up what is 7-OH on his phone.

7-OH, short for 7-hydroxymitragynine, is an opioid-like compound found in trace amounts in the kratom leaf. Sellers now concentrate it, or make it from other kratom compounds, and sell it as tablets, gummies, and shots. In those forms, it acts far more like a strong opioid than plain kratom.

Many 7-OH products are labeled as kratom, so a man who uses kratom, or his family, may not know how different they are. That difference matters once daily use turns into dependence, because 7-OH is then treated much like other opioid problems, with medical care and drug rehab built for men in Phoenix.

What Is 7-OH?

Man discussing recovery support with a counselor in a welcoming room.

7-OH is one of many natural compounds in kratom. Kratom comes from Mitragyna speciosa, a tropical tree native to Southeast Asia, and the kratom plant has long been used there in herbal medicine.

An Active Metabolite of the Kratom Leaf

The leaf holds many alkaloids, the active compounds that give a plant its effects. Mitragynine is the main one. 7-OH is a minor alkaloid found only in small quantities, less than 2 percent of the total alkaloid content in natural leaves.

The FDA reviewed testing of 341 consumer-provided kratom product samples and reported a mean 7-OH concentration of 0.01 percent [1]. These were product samples, not a uniform set of fresh leaves. That tiny share is why the answer to what is kratom looks so different from the answer for 7-OH.

The body adds some 7-OH because liver enzymes, mainly one called CYP3A4, turn some mitragynine into it. That makes 7-OH an active metabolite, meaning a breakdown product that has its own effects.

How Concentrated Kratom Products Are Made and Sold

FDA scientists say many concentrated 7-OH products are likely made in a lab from mitragynine or kratom extracts, which makes them semi-synthetic. The result has high concentrations of a compound the leaf holds only in trace amounts. Products sold as 7-OH come in several forms:

  • Chewable tablets and tablets that dissolve under the tongue
  • Gummies
  • Liquid shots
  • Powders and capsules
  • Liquid extracts

The FDA says these products are sold online and in gas stations, corner stores, and vape shops [2]. Smoke shops and convenience stores in many states also sell them, often next to kratom preparations, so they are widely available. Lab tests have found more 7-OH in some products than their product labeling states.

Because 7-OH is sold under the kratom name, it raises the question: Is kratom an opioid? The answer for the leaf is mixed. Concentrated 7-OH clearly behaves like one.

Why 7-OH Hits Harder Than Kratom Leaf

7-OH binds to the same opioid receptors in the brain as morphine, oxycodone, and heroin. Some researchers call kratom’s compounds partial agonists, which means they turn these receptors on only part of the way, but studies disagree. Concentrated 7-OH still causes strong opioid-like effects.

Potency in Lab Studies

In one lab test on animal tissue, 7-OH was about 13 times more potent than morphine [1]. The same test found it about 46 times more potent than mitragynine. The test measured inhibition of contractions in isolated guinea pig intestinal tissue, not pain relief or overdose risk in people.

Leaf kratom acts on opioid receptors much more weakly. Even so, regular leaf use can lead to withdrawal from everyday kratom use, which is usually mild to moderate.

7-OH and Kratom Products Compared

This table compares plain leaf with concentrated 7-OH products on their main risks.

FeatureKratom LeafConcentrated 7-OH Products
What it isDried leaf of a tropical treeTablets, gummies, shots, and extracts made to deliver 7-OH
7-OH contentTrace amounts; one consumer-product study averaged 0.01 percentHigh potency, far above leaf levels
Main effectsStimulant-like at low doses, sedating at high dosesStrong opioid effects
FDA-approved medical useNoneNone
Federal status in October 2026Not scheduledProposed for Schedule I, not yet in effect

Breathing and Overdose Risk

The biggest danger of 7-OH is respiratory depression, which means breathing that slows down or stops. In animal studies, 7-OH caused respiratory depression at lower doses than morphine. That is a potency finding, not a direct measure of relative risk in people. Mixing it with alcohol, sedatives, or other substances that also slow breathing raises the danger.

The same risk applies to kratom and alcohol, a pair that shows up often in poison center cases. Alcohol and opioids both slow breathing, and together they can slow it more than either one alone.

Naloxone is the medicine that reverses opioid overdose. The American College of Medical Toxicology (ACMT) reports that naloxone has reversed breathing problems caused by 7-OH [3]. If someone in your life uses 7-OH, carry naloxone, and still call 911 if his breathing slows or he stops responding.

The Dangers of 7-OH: What the Numbers Show

Poison center experts warn that 7-OH cases are climbing fast. America’s Poison Centers counted 593 exposures to 7-OH in 2025 [4]. In the first six months of 2026, that number reached 901.

Among patients with 7-OH-only exposures reported to poison centers in the advisory’s dataset, 20.5 percent were hospitalized. This is not the hospitalization rate among everyone who uses 7-OH. Poison centers have seen these health problems after 7-OH use:

  • Nausea and vomiting
  • Confusion or agitation
  • Sweating and a racing heart
  • High blood pressure
  • Trouble breathing
  • Deep sleepiness or passing out
  • Seizures

The Drug Enforcement Administration has found 7-OH in 85 toxicology cases since 2019, and 55 of them were fatal [5]. Detection does not prove 7-OH caused each death, and these selected toxicology cases do not establish a fatality rate among users.

Dependence, Withdrawal, and Opioid Addiction

Men attending a community discussion about recognizing overdose.

ACMT reports that people using 7-OH have developed dependence, tolerance, and withdrawal typical of other opioids. Tolerance means needing more to get the same effect. Dependence means the body needs the drug to feel normal.

When a dependent man stops, opioid withdrawal can set in, with aches, sweating, diarrhea, anxiety, and strong cravings. Withdrawal symptoms similar to coming off pain pills are a big reason 7-OH withdrawal is hard to get through alone.

Over time, this can become opioid use disorder, the medical name for opioid addiction. Doctors sometimes say kratom use disorder when kratom products are the main substance. Some people started taking kratom to ease opioid withdrawal, but the FDA has not approved kratom or 7-OH for that use.

Treatment for 7-OH addiction looks a lot like treatment for other opioid problems. ACMT notes that buprenorphine, a medicine for opioid use disorder, has been used with success to treat kratom and 7-OH withdrawal. Addiction medicine doctors often pair medication with counseling and support groups, so talk with a doctor or other healthcare provider before you stop.

As of October 2026, 7-OH is not federally scheduled, but that is changing:

  • July 29, 2025: the Food and Drug Administration recommended scheduling certain 7-OH products, but not natural kratom leaf.
  • July 6, 2026: the DEA published an initial notice of intent for 7-OH above a threshold; it later withdrew that notice and issued the revised October notice.
  • August 26, 2026: mitragynine pseudoindoxyl, MGM-15, and MGM-16 entered Schedule I on a temporary basis, but 7-OH did not [6].
  • October 14, 2026: the DEA’s notice of intent for 7-OH was published in the Federal Register.
  • On or after November 13, 2026: the temporary order can be published, so it is not yet in effect.

The notice uses concentration and ratio thresholds for 7-OH and mitragynine pseudoindoxyl, separately or combined: more than 1 mg/g in solids, more than 1 mg/mL in liquids, or a mitragynine-to-combined-compounds ratio below 100 to 1 [5]. Natural kratom leaf with only trace amounts of 7-OH falls below that threshold.

The American Kratom Association, a kratom industry trade group, said in July 2026 that it backs the DEA plan. Some states have banned 7-OH products with emergency rules. Arizona has its own kratom law with limits on 7-OH, and there is a full breakdown of the state rules here.

Common Questions About 7-OH

Is 7-OH an Opioid?

7-OH is an opioid by its pharmacology. As of October 16, 2026, its proposed federal Schedule I controls have not taken effect. It binds to the brain’s opioid receptors, causes opioid-like effects, and can slow breathing. The FDA calls concentrated 7-OH an emerging opioid threat, and the DEA has moved to place concentrated products in Schedule I.

Does 7-OH Show Up on a Drug Test?

7-OH usually does not show up on a standard panel because the federal workplace panel does not include kratom, mitragynine, or 7-OH. Specialized lab tests can look for kratom compounds when an employer, court, or treatment program orders them. The page on whether kratom shows up on a drug test explains how.

Is 7-OH Safer Than Kratom?

7-OH is not safer than kratom because concentrated 7-OH is far more potent than leaf kratom. Lab studies show stronger opioid effects, and poison center reports involving 7-OH rose sharply in 2025 and 2026. Neither one has FDA approval for any therapeutic effects.

Getting Help for 7-OH Addiction

If 7-OH or kratom has taken over your days, you do not have to fix it alone. A call to our team at Into Action Recovery is a good start, and you can first read how our drug rehab for men works.

For free, confidential help, call the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline at 1-800-662-4357. Call or text 988 in a crisis, or call 911 for an overdose.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Federal rules on 7-OH were changing when this was written in October 2026. If you or someone you know is in crisis, call or text 988. In an emergency, call 911.

Sources

  1. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat. July 2025. https://www.fda.gov/media/187899/download
  2. U.S. Food and Drug Administration. FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers. July 29, 2025. https://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers
  3. American College of Medical Toxicology. ACMT Position Statement: 7-Hydroxymitragynine. August 2026. https://www.acmt.net/wp-content/uploads/2026/08/ACMT-Position-Statement-7-Hydroxymitragynine-8-5-26.pdf
  4. America’s Poison Centers. Health Advisory: Serious Illnesses Associated with Kratom and 7-OH Products. July 8, 2026. https://poisoncenters.org/news-alerts/13651143
  5. Drug Enforcement Administration. Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I (notice of intent), 91 FR 65370. October 14, 2026. https://www.federalregister.gov/documents/2026/10/14/2026-20943/schedules-of-controlled-substances-temporary-placement-of-7–hydroxymitragynine-and-mitragynine
  6. Drug Enforcement Administration. Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (temporary scheduling order). Federal Register Doc. 2026-17429. August 26, 2026. https://www.govinfo.gov/content/pkg/FR-2026-08-26/html/2026-17429.htm

About the Reviewer

Chris Burwash

Chris Burwash

CEO & Founder

Chris Burwash is the Founder and Chief Executive Officer of Into Action Recovery and a man in long-term recovery with more than two decades of experience working in addiction treatment for men. His personal journey and professional work have been dedicated to helping men break free from addiction and rebuild stable, meaningful lives.

Our work is simple: men get better here—and they stay better.

If you’re a man or you know and love a man that is ready for real change, Into Action Recovery offers a proven path forward.

Take the first step today.